MAPK8 and COVID-19: In line with the suggested strategy for inhibition of JNK pathway in COVID-19 critically-ill patients as a promising therapeutic approach [66], here we present the first clinical study revealing the increased JNK expression in PBMCs to be a significantly associated with COVID-19-related mortality (Fig 3).